Laos bolsters molnupiravir production for COVID-19 treatment
Laos is to step up production of its antiviral drug molnupiravir with the trade name of Molacovir to serve treatment of COVID-19 patients with mild symptoms.

Dr Lahounh Chanthabout, Managing Director of State
Enterprise Pharmaceutical Factory No. 3 – the medicine manufacturer in Laos,
said demand for the medication is to triple this year, Vientiane Times reports.
The factory, which began producing the drug in December last
year, has been unable to meet demand because of the increase in the number of
COVID-19 patients.
The factory is selling Molacovir at 400,000 LAK (36 USD) for
one course of treatment, which lasts for five days.
The drug pilot programme is targeting people aged 18 and
over who have mild or moderate symptoms of COVID-19 and are in the early stages
of the disease. To qualify for treatment, patients must not show signs of
pneumonia or oxygen shortage.
Laos recorded 805 new COVID-19 cases and seven fatalities across
the country in the past 24 hours, announced the country’s Ministry of Health on
January 13.
The national count reached 122,241, with 471 deaths./.